Avid Bioservices Inc (CDMO)

[entdoc]

goodJohn, thanks for your efforts in the labyrinthine world of immunology. You wrote, "Immunocore has created a world-leading platform of bi-specific biological drugs, called ImmTACs, which exploit the power of T Cell Receptors (TCRs) to recognise intracellular changes that occur during cancer or viral infection. THIS UNIQUE RCOGNITION ABILITY of TCRs sets them apart from traditional antibody-based therapies that can only recognise changes on the surface of cells, and provides, for the first time, the ability to develop extremely potent targeted therapies for cancers that are currently poorly served. A particular feature is that the ImmTACs can be directed to target and destroy only the cancerous cells, avoiding damage to healthy cells.
It should be said that BAVITUXIMAB is also capable of recognizing changes on the surface of cancer/viral cells which reflect changes inside a cell infected with cancer/virus. Membrane phosphatidylserine (PS) flips inside out, presenting a surface antigen to target, an antigen which was previously intracellular.